CCRM

CCRM supports the development & commercialization of regenerative medicines & associated enabling technologies, with a specific focus on cell & gene therapy.

[CCRM @CCRM_ca]

We're pleased to share our 2025 #annualreport: Reimagining The Possible. It was a year defined by resilience, focus & forward momentum. Read about our collab w/ @IonQ_Inc, progress w/ @CCRM_au & Nordic, successes at our #GMP #CDMO & @CATTI_Training & more https://t.co/jfDPHZVleh

[ISSCR @ISSCR]

📢 The ISSCR is now accepting nominations for the 2027 ISSCR Board of Directors and the Society's annual awards. Nominations are due 16 October. Learn more 👉https://t.co/fGkqgyJYjF

[ASGCT @ASGCTherapy]

When knowledge is shared across sectors, the rare disease community can find answers faster and close gaps in care and access. Join the 2026 NORD Breakthrough Summit, Oct. 25–27 in Washington, DC, to exchange ideas and build new connections.

ASGCT staff will be there to connect you with patient education resources (including our new coloring book!), and discuss the latest policies affecting rare disease research and individuals.

Learn more ➡️ https://t.co/6JU0Jm2gJs

#NORDSummit #RareDisease

[CCRM @CCRM_ca]

@bradwouters @thePMCF That's wonderful news!

[Genetic Engineering & Biotechnology News @GENbio]

Last chance—GEN's State of Biotech is tomorrow.

Maraganore. Orkin. Google Cloud's Shweta Maniar. The Biotech Hangout hosts. And John Sterling's exit interview after four decades as GEN's Editor in Chief.

Free registration: https://t.co/j8SYMpSeHX
#biotech #stateofbiotech

[CCRM @CCRM_ca]

Musings from @MichaelMay5 via The Medicine Maker's Power List. Shoutouts to @IonQ_Inc, @BlueRockTx and #DeepTechBioLab https://t.co/dCgEgSe5T3

[CCRM @CCRM_ca]

Is this you?

[Signals @Signalsblogs]

📣 Signals is looking for talented bloggers to write about the #regenerativemedicine and #CGT fields. https://t.co/T6iLk6T5tp
If you’re passionate about cutting-edge science and can turn complex ideas into compelling content, we want to hear from you. DM us to learn more #scicomm

[CCRM @CCRM_ca]

Timely topic

[Signals @Signalsblogs]

Just as @CBCNews is reporting about doctor #deepfake videos, @msstaceyerin has a timely blog post exploring the topic of who we can trust online with our health: https://t.co/91RzTldzrk Studies from @CaulfieldTim, Megan Munsie, @pewresearch @CMA_Docs

[Signals @Signalsblogs]

Just as @CBCNews is reporting about doctor #deepfake videos, @msstaceyerin has a timely blog post exploring the topic of who we can trust online with our health: https://t.co/91RzTldzrk Studies from @CaulfieldTim, Megan Munsie, @pewresearch @CMA_Docs

[CCRM @CCRM_ca]

@SickKidsNews Congratulations SickKids! You make Canadians proud.

[Alliance for Regenerative Medicine (ARM) @alliancerm]

A fifth cell and gene therapy product has been approved in the US this year.

Today, the FDA announced approval of an AAV gene therapy developed by ARM member Ultragenyx to treat pediatric patients with Sanfilippo syndrome Type A. 1/2
https://t.co/icwC3ApDJI

[CCRM @CCRM_ca]

Banner week for #DeepTechBioLab: 1st a workshop at @IEEEQuantumWeek & then an event in the @biolabs @UofT space, with presentations & a panel. Want to learn more how we are bringing together #DeepTech companies with #lifesciences? https://t.co/GAOtNBvnIw @IonQ_Inc @KausarSamli

[CCRM @CCRM_ca]

How do we make CGTs more accessible to patients globally? In the new episode of our podcast, @bambi_grilley & #StaciArnold explore manufacturing & delivery challenges, regulation, P3s & more. Listen where you stream podcasts or at https://t.co/xFPIF5LSsK. @KristaLambComms

[Signals @Signalsblogs]

📣 Signals is looking for talented bloggers to write about the #regenerativemedicine and #CGT fields. https://t.co/T6iLk6T5tp
If you’re passionate about cutting-edge science and can turn complex ideas into compelling content, we want to hear from you. DM us to learn more #scicomm

[ASGCT @ASGCTherapy]

Submit an abstract to the Inaugural Canadian Gene and Cell Therapy Conference by October 1!

Early-career investigators and trainees are invited to submit abstracts highlighting advances across the cell and gene therapy landscape from basic discovery through to clinical implementation. Accepted abstracts will be presented as posters, with selected submissions invited for short oral presentations.

For more information or to submit an abstract, visit https://t.co/yNCw0lc23u.

[Ry Leahy @RySciComms]

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

https://t.co/vCmnsK6V5t

[UHN Research @UHN_Research]

Thank you to @CIHR_IRSC for supporting this research!

Learn more about how the LUMI-Lab and @UHN researchers (@BowenLi_Lab, @BoWang87, @HAOTIANCUI1, @Yuexulab) are using #AI-enabled robotics to accelerate molecular discovery.

➡️: https://t.co/ADcW75G4I1

[ISSCR @ISSCR]

The ISSCR recently submitted comments to the #FDA draft guidance for Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing.

Read the comments.

https://t.co/uKPxjZi5XH

[BioSpace @biospace]

The FDA’s proposal to offer 50% off application fees for drugs with early-stage trials conducted in the U.S. is unlikely to achieve the intended result. What biotechs really want is speed.

https://t.co/oRbPaBn64r

[CCRM @CCRM_ca]

@IonQ_Inc See you there! Looking forward to it.

[CCRM @CCRM_ca]

The 2026 #CellsISee People’s Choice Award voting is now open! "Like" your favourite and the lucky winner will receive $500 at #TMM2026. The #sciart #contest is co-hosted with @StemCellNetwork Vote here: https://t.co/HaWmUnm6Ed Pls RT